Misplaced Pages

Chattem

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
American healthcare product company
This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.
Find sources: "Chattem" – news · newspapers · books · scholar · JSTOR (April 2007) (Learn how and when to remove this message)
Chattem, Inc.
Company typeSubsidiary
Industryhealthcare
Over-the-counter-drug manufacturing
FoundedTennessee (January 30, 1879, as the Chattanooga Medicine Company)
HeadquartersChattanooga, Tennessee
Key people
ProductsAllegra, Gold Bond, ACT Mouthwash, Cortizone-10, Flexall, IcyHot, Sun-In, Ultra Swim, Pamprin, Premsyn, Kaopectate, Dexatrim, Aspercreme, Selsun Blue, Nasacort, Unisom, Capzasin, Benzodent, Herpecin-L, Garlique, and New Phase
Revenue$1 Billion (USD) (2013)
Number of employees536
ParentSanofi
WebsiteChattem.com

Chattem, Inc. is an American, Chattanooga, Tennessee-based, producer and marketer of over-the-counter healthcare products, toiletries, dietary supplements, topical analgesics, and medicated skin care products. Originally named the Chattanooga Medicine Company, the company’s brand portfolio holds twenty-two brands including Allegra, Gold Bond, Flexall, IcyHot, Rolaids, Sun-In, Pamprin, Dexatrim, Aspercreme, and Selsun Blue. The company produces two-thirds of its products at its Chattanooga production facilities with the remaining produced by third-party producers. The company is a subsidiary of the French multinational pharmaceutical company Sanofi.

The company’s brands are sold nationally through mass merchandiser, drug and food retailers. In 2005, 70% of the firm's sales were made through its top ten customers, which include Wal-Mart, Walgreens, and Kroger. Sales to Wal-Mart constituted 36% of Chattem’s total sales in 2005. Chattem supports these sales with a forty-five-person sales force and broadcast media advertising. Chattem has market penetration in the United States, Europe, Canada, Latin America, and the Caribbean.

History

  • Chattem was founded by Zeboim Cartter Patten as the Chattanooga Medicine Company in 1879. The company incorporated in 1909 and has remained in Chattanooga, Tennessee, to this day.
  • During World War II, the Chattanooga Medicine Company turned into a major supplier of K-Rations to the US Army, producing 34 million rations from 1942 to 1945, earning 5 "E" Awards for support of war efforts.
  • The firm adopted Chattem as its name and went public in 1969.
  • Chattem’s top and bottom lines grew significantly from 1989 through 1992. The source of this growth was the company’s strategy of purchasing under-marketed consumer brands and aggressively marketing those in its portfolio. In 1993, Chattem experienced a 14% decline in sales from the loss of Warner-Lambert’s Rolaids business. To fund a one-time special dividend in 1994, $75 million in high-yield bonds were issued.
  • In January 2013, Chattem acquired the full rights to Rolaids, which had seen its brand wounded under the ownership of Johnson & Johnson's McNeil Consumer Healthcare with a series of product recalls and quality control issues throughout 2010 that ended with most of the Rolaids line discontinued. In September, 2013 Chattem returned Rolaids to the market with new trade dress, though production of Rolaids is not expected to return to Chattanooga.
  • In March 2014, Chattem sold Dexatrim to NVE Pharmaceuticals.

Recent events

In October 2006, Chattem announced it would acquire five brands for $410 million as a result of the merger between Johnson & Johnson and the consumer healthcare business of Pfizer. These brands are:

Pending the US government’s approval of the merger of Johnson & Johnson and Pfizer Consumer Healthcare, Chattem will acquire five brands divested from the firms. Chattem has announced it expects to take possession of the brands around January 2007. These mature brands will provide $150 million in additional revenue to Chattem per year.

On December 21, 2009, Paris-based (France) Sanofi, the world's fourth largest drugmaker, said it was acquiring Chattem in a $1.9 billion cash deal. Sanofi said the acquisition would be completed by the first quarter of 2010.

Current brands

Chattem manufactures many over-the-counter healthcare products. They are marketed in three categories: pain relief, skin & hair care, and health & wellness.

Pain relief

Skin & hair care

Health & wellness

References

  1. "Archived copy" (PDF). Archived from the original (PDF) on 2012-05-08. Retrieved 2011-11-12.{{cite web}}: CS1 maint: archived copy as title (link)
  2. "Chattem". Archived from the original on 2011-11-02. Retrieved 2011-11-12.
  3. Friedman, Alexi (8 January 2013). "Johnson & Johnson sells its troubled Rolaids brand to Sanofi". The Star-Ledger. Retrieved 9 September 2013.
  4. Pare, Mike (9 January 2013). "Rolaids next on Chattanooga-based Chattem's plate". Chattanooga Times Free Press. Retrieved 9 September 2013.
  5. "NVE Pharmaceuticals Announces the Acquisition of Dexatrim to the Stacker2 Family". PRWeb. March 11, 2014. Retrieved September 26, 2018.
  6. "Sanofi to Acquire Chattem", The Economic Times (December 22, 2009)

External links

• Official website

Sanofi
Predecessors
CEOs
Main products
Cardiovascular
Thrombosis
Oncology
Diabetes
Central nervous system
Internal medicine
Subsidiaries
Chattem Inc.
Brands
Others
Chattem Inc.
Subsidiary of Sanofi
Brands
Categories: